TP53 and breast carcinoma: In this study, we performed high-throughput screening of more than 30 000 compounds in HDQ-P1 human breast cancer cells harbouring homozygous R213X nonsense mutant TP53 [32] and identified C47 and C61 as novel candidate readthrough-inducing compounds.